Status: Recruiting
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Participants needed: 400
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Leiden University Medical CenterUpdated: Feb 13, 2026Locations: 11Duration: 1 Year
Eligibility criteria
Congenital heart defect. [+2]